???global.info.a_carregar???
I’m a post-doctoral researcher with over 15 years of experience in cellular and molecular biology applied to cancer research. I completed my degree and MSc in Pharmacy at the University of Coimbra in Portugal. In 2008, I was awarded a fellowship for a short-term stay at Dr. Enrique de Alava’s group in Salamanca, where a few years later I obtained a Ph.D. fellowship granted by Fundação para a Ciência e Tecnologia, from Portugal. After earning my Ph.D. in cancer molecular biology from the Cancer Research Center-Universidad de Salamanca, I joined Dr. Enrique de Álava’s new group in Seville. I have been a post-doctoral fellow at the Institute of Biomedicine of Seville, working in close touch with the clinical setting of pediatric sarcomas. Additionally, I earned an MSc degree in Clinical Trials from the University of Seville. During my post-doctoral stage, I had the chance to work at the Institute of Cancer Research, in London, under the supervision of Dr. Janet Shipley, generating 3D models and optimizing new in vitro invasion protocols. Recently, I’ve been enjoying a visiting research grant at Dr. João Moreira’s group, the Tumor Microenvironment, and Targeted Therapies group at the CNC-Universidade de Coimbra, in Portugal. During the last few years, my research has been focused on the tumoral microenvironment (transmembrane proteins and extracellular vesicles) and the development of new in vitro and in vivo research models to better understand the biology underlying the tumoral progression of rare pediatric sarcomas. In particular, I have established a new research line, focused on the study of desmoplastic small round cell tumors, and am currently developing genetically engineered models to mimic this disease I have obtained individual funding to carry out my projects and had the opportunity to supervise several MSc and Ph.D. students. My motivation has been and will always be directed towards improving the clinical outcome of patients and effectively translating molecular findings to the clinical setting.
Identification

Personal identification

Full name
Ana Teresa Amaral

Citation names

  • Amaral, Ana

Author identifiers

Ciência ID
FD1F-F6B7-E53E
ORCID iD
0000-0001-7887-4814
Google Scholar ID
https://scholar.google.com/citations?user=mJF59dYAAAAJ&hl=pt-PT

Websites

Knowledge fields

  • Medical and Health Sciences - Medical Biotechnology - Gene-based Diagnostics and Therapeutic Interventions

Languages

Language Speaking Reading Writing Listening Peer-review
Portuguese (Mother tongue)
English Proficiency (C2) Proficiency (C2) Proficiency (C2) Proficiency (C2) Proficiency (C2)
Spanish; Castilian Proficiency (C2) Proficiency (C2) Proficiency (C2) Proficiency (C2) Proficiency (C2)
Italian Intermediate (B1) Intermediate (B1) Elementary (A2) Intermediate (B1) Beginner (A1)
French Elementary (A2) Elementary (A2) Elementary (A2) Intermediate (B1) Beginner (A1)
Education
Degree Classification
2014 - 2015
Concluded
Clinical Trials (Master)
Universidad de Sevilla, Spain
8.3/10
2009 - 2014/09/18
Concluded
Biologia Molecular y Clínica del Cancer (Doctor of Philosophy)
Major in Biologia Molecular y Clínica del Cancer
Universidad de Salamanca, Spain

Instituto de Biología Molecular y Celular del Cáncer, Spain
"The pathogenesis of Ewing Sarcoma: Implications of Mesenchymal Stem Cells and New Therapeutic Strategies" (THESIS/DISSERTATION)
Sobresaliente, Cum Laude
2008/09 - 2010/12
Concluded
Biologia molecular y Clinica del Cancer (DEA)
Major in Molecular oncology
Universidad de Salamanca, Spain
"Estudio de la Célula Stem Mesenquimal en Sarcoma de Ewing" (THESIS/DISSERTATION)
2002 - 2008
Concluded
Ciências Farmacêuticas (Mestrado integrado)
Universidade de Coimbra Faculdade de Farmácia, Portugal
15
Affiliation

Science

Category
Host institution
Employer
2024/09/01 - Current Auxiliary Researcher (Research) Tumor Microenvironment and Targeted Therapies group-CNC-UC, Portugal
ERA Fellowships - European Research Executive Agency, Portugal
2021 - Current Science and Technology Management España Ministerio de Ciencia e Innovación, Spain
2023/05/04 - 2024/08/31 Auxiliary Researcher (Research) Universidade de Coimbra Instituto de Investigação Clínica e Biomédica de Coimbra, Portugal
2023/03/01 - 2023/04 Science and Technology Management Nordic Innovators P/S, Denmark
2014/12/31 - 2022/12/31 Auxiliary Researcher (Research) Instituto de Biomedicina de Sevilla, Spain
Instituto de Biomedicina de Sevilla, Spain
2022/09/01 - 2022/12/01 Visiting Researcher (Research) Universidade de Coimbra, Portugal
Tumor Microenvironment and Targeted Therapies group-CNC-UC, Portugal
2018/09 - 2018/12 Visiting Researcher (Research) The Institute of Cancer Research, United Kingdom
The Institute of Cancer Research, United Kingdom
2009 - 2014 Researcher (Research) Instituto de Biología Molecular y Celular del Cáncer, Spain
Instituto de Biología Molecular y Celular del Cáncer, Spain
2008 - 2009 Research Trainee (Research) Instituto de Biología Molecular y Celular del Cáncer, Spain
Instituto de Biología Molecular y Celular del Cáncer, Spain
Projects

Grant

Designation Funders
2024/01/09 - 2026/08/31 ERA Fellowships (HORIZON-WIDERA-2022-TALENTS-04)
Post-doc
2022/01/01 - 2023 Tailored adoptive cellular immunotherapy for Ewing Sarcoma
Post-doc
Instituto de Biomedicina de Sevilla, Spain

Fundación Josep Carreras contra la Leucemia, Spain
Obra Social La Caixa
Ongoing

Contract

Designation Funders
2023/05/01 - 2024/08/31 CInTech: Technological Hub for Innovation, Translation and Industrialization of Complex Injectable Drugs
Post-doc Fellow
Universidade de Coimbra, Portugal

Bluepharma, Portugal
Ongoing
2021 - 2023 Integrative molecular-testing platform for precision diagnostics and personalized care of sarcoma patients
Post-doc
Instituto de Biomedicina de Sevilla, Spain

Hospital Universitario Virgen del Rocío, Spain
Fundacion Maripaz Jimenez Casado
Ongoing
2020 - 2023 Study of the prognostic and functional role of mesenchymal stem cell markers Endoglin and ALCAM in the disease progression of Clear cell sarcomas (CCS) and Desmoplastic small Round cell tumors (DSRCT)
P18-RT-735
Principal investigator
Instituto de Biomedicina de Sevilla, Spain
Junta de Andalucía
Concluded
2020 - 2023 New insights into the Desmoplastic small round cell tumour: comprehensive molecular characterization to identify therapeutic targets and new biomarkers
400300200313
Principal investigator
Instituto de Biomedicina de Sevilla, Spain
Grupo Espanol Investigacion Sarcomas
Ongoing
2019 - 2023 Translational assessment of predictive factors of response of Ewing sarcoma to genotoxic therapy
S1900239
Principal investigator
Instituto de Biomedicina de Sevilla, Spain

Hospital Universitario Virgen del Rocío, Spain

University College London, United Kingdom

University of Michigan, United States
Sarcoma Foundation of America
2019 - 2022/12 CIBERONC-Centro de Investigacio Biomedica en RED: Low prevalence tumours program
Post-doc
Centro de Investigación Biomédica en Red de Cáncer, Spain
Ongoing
2021 - 2022 Intratumoral heterogeneity in t-sarcomas: A silver lining for precision therapeutics
PI20-0003
Post-doc
Instituto de Biomedicina de Sevilla, Spain
Instituto de Salud Carlos III
Ongoing
2020 - 2022 Evaluación de STAT6 como biomarcador de diagnóstico de precisión y diana terapéutica en Tumor Fibroso Solitario
PI-0061-2020
Post-doc
Instituto de Biomedicina de Sevilla, Spain

Hospital Universitario Virgen del Rocío, Spain
Junta de Andalucía
Ongoing
2018 - 2021 Evaluation of the clinical potential of the vesicular crosstalk in response to drugs in the context of Ewing sarcoma. PI-0040-2017
PI-0040-2017
Principal investigator
Instituto de Biomedicina de Sevilla, Spain
Junta de Andalucía
2018 - 2020 Nuevas dianas terapéuticas en el sarcoma de Ewing a través del estudio del proceso metastásico
PI1700464
Post-doc
Instituto de Biomedicina de Sevilla, Spain
Instituto de Salud Carlos III
Concluded
2018 - 2019 PROYECTO 3D-ID CULTIVOS 3D PERSONALIZADOS PARA SELECCIÓN DE TRATAMIENTO PARA PACIENTES DE CÁNCER EN MEDICINA DE PRECISIÓN
Post-doc
Instituto de Biomedicina de Sevilla, Spain

STEMTEK THERAPEUTICS SL, Spain

FUNDACIÓN ONKOLOGIKOA FUNDAZIOA, Spain

Institut d'Investigació Biomèdica de Bellvitge, Spain
Cancelled
2017 - 2018 PROspective VAlidation of Biomarkers in Ewing Sarcoma for personalized translational medicine
Post-doc
Hospital Universitario Virgen del Rocío, Spain

IRCCS Istituto Ortopedico Rizzoli, Italy

St James's University Hospital, United Kingdom

Institut Curie, France

Klinikum rechts der Isar der Technischen Universität München, Germany
European Commission
Concluded
2014 - 2017 Nuevas dianas terapéuticas en el sarcoma de Ewing: estudio del micromedioambiente
PI14/01466
Post-doc
Instituto de Biomedicina de Sevilla, Spain
Instituto de Salud Carlos III
Concluded
2014 - 2016 ENDOWING RELEVANCIA DE LA ENDOGLINA EN LA PATOLOGÍA DEL SARCOMA DE EWING: DESARROLLO DE TRATAMIENTOS PERSONALIZADOS INNOVADORES
Post-doc
Instituto de Biomedicina de Sevilla, Spain

Oncomatryx, Spain
Concluded
Outputs

Publications

Conference poster
  1. Joaquin Olmedo-Pelayo; Amaral, Ana; Álava, Enrique De. "EWS::FLI1-DHX9 interaction alters R-loop metabolism promoting Ewing sarcoma sensitivity to genotoxic agents". Paper presented in ANNUAL CONGRESS OF THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH EACR 2023, 2023.
  2. Lobo-Selma, Laura; Amaral, Ana; Carmen Salguero Aranda; Álava, Enrique De. Corresponding author: Carmen Salguero Aranda. "Unravelling the molecular landscape of Desmoplastic Small Round Cell Tumor". Paper presented in ANNUAL CONGRESS OF THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH EACR 2023, 2023.
Journal article
  1. Ana Amaral; Carmen Salguero Aranda; Joaquín Olmedo-Pelayo; Enrique de Alava; Ana Teresa Amaral; Juan Diaz-Martin. "Genetic Alterations and Deregulation of Hippo Pathway as a Pathogenetic Mechanism in Bone and Soft Tissue Sarcoma". Cancers 14 24 (2022): 6211-6211. http://dx.doi.org/10.3390/cancers14246211.
    10.3390/cancers14246211
  2. Puerto-Camacho, Pilar; Díaz-Martín, Juan; Olmedo-Pelayo, Joaquín; Bolado-Carrancio, Alfonso; Salguero-Aranda, Carmen; Jordán-Pérez, Carmen; Esteban-Medina, Marina; et al. Corresponding author: Amaral, Ana Teresa. "Endoglin and MMP14 Contribute to Ewing Sarcoma Spreading by Modulation of Cell–Matrix Interactions". International Journal of Molecular Sciences 23 15 (2022): 8657. http://dx.doi.org/10.3390/ijms23158657.
    Open access • Published • 10.3390/ijms23158657
  3. Martí, Juan Manuel; Garcia-Diaz, Angel; Delgado-Bellido, Daniel; O'Valle, Francisco; González-Flores, Ariannys; Carlevaris, Onintza; Rodríguez-Vargas, José Manuel; et al. "Selective modulation by PARP-1 of HIF-1a-recruitment to chromatin during hypoxia is required for tumor adaptation to hypoxic conditions". Redox Biology 41 (2021): 101885. http://dx.doi.org/10.1016/j.redox.2021.101885.
    10.1016/j.redox.2021.101885
  4. González Muñoz, Teresa; Amaral, Ana Teresa; Puerto-Camacho, Pilar; Peinado, Héctor; de Álava, Enrique. "Endoglin in the Spotlight to Treat Cancer". International Journal of Molecular Sciences 22 6 (2021): 3186. http://dx.doi.org/10.3390/ijms22063186.
    10.3390/ijms22063186
  5. "Hippo pathway effectors YAP1/TAZ induce an EWS–FLI1 -opposing gene signature and associate with disease progression in Ewing sarcoma". The Journal of Pathology 250 4 (2020): 374-386. http://dx.doi.org/10.1002/path.5379.
    10.1002/path.5379
  6. "Breakthrough Technologies Reshape the Ewing Sarcoma Molecular Landscape". Cells 9 4 (2020): 804-804. http://dx.doi.org/10.3390/cells9040804.
    10.3390/cells9040804
  7. "Preclinical Efficacy of Endoglin-Targeting Antibody–Drug Conjugates for the Treatment of Ewing Sarcoma". Clinical Cancer Research 25 7 (2019): 2228-2240. http://dx.doi.org/10.1158/1078-0432.ccr-18-0936.
    10.1158/1078-0432.ccr-18-0936
  8. "DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma". Nature Medicine 23 3 (2017): 386-395. http://dx.doi.org/10.1038/nm.4273.
    10.1038/nm.4273
  9. "Ex vivo identification and characterization of a population of CD13high CD105+ CD45- mesenchymal stem cells in human bone marrow". Stem Cell Research & Therapy 6 1 (2015): http://dx.doi.org/10.1186/s13287-015-0152-8.
    10.1186/s13287-015-0152-8
  10. "The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin". Oncotarget 6 22 (2015): 18875-18890. http://dx.doi.org/10.18632/oncotarget.4303.
    10.18632/oncotarget.4303
  11. "Bone microenvironment signals in osteosarcoma development". Cellular and Molecular Life Sciences 72 16 (2015): 3097-3113. http://dx.doi.org/10.1007/s00018-015-1918-y.
    10.1007/s00018-015-1918-y
  12. "Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination with Anti-IGF Signaling Agents". Clinical Cancer Research 21 6 (2015): 1373-1382. http://dx.doi.org/10.1158/1078-0432.ccr-14-1688.
    10.1158/1078-0432.ccr-14-1688
  13. "Characterization of Human Mesenchymal Stem Cells from Ewing Sarcoma Patients. Pathogenetic Implications". PLoS ONE 9 2 (2014): e85814-e85814. http://dx.doi.org/10.1371/journal.pone.0085814.
    10.1371/journal.pone.0085814
  14. "Innovative Therapies in Ewing Sarcoma". Advances in Anatomic Pathology 21 1 (2014): 44-62. http://dx.doi.org/10.1097/pap.0000000000000003.
    10.1097/pap.0000000000000003
  15. "IGF1R Signaling in Ewing Sarcoma Is Shaped by Clathrin-/Caveolin-Dependent Endocytosis". PLoS ONE 6 5 (2011): e19846-e19846. http://dx.doi.org/10.1371/journal.pone.0019846.
    10.1371/journal.pone.0019846
  16. "The Clinical Relevance of Molecular Genetics in Soft Tissue Sarcomas". Advances in Anatomic Pathology 17 3 (2010): 162-181. http://dx.doi.org/10.1097/pap.0b013e3181d98cbf.
    10.1097/pap.0b013e3181d98cbf
  17. "Stable interference of EWS–FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target". British Journal of Cancer 101 1 (2009): 80-90. http://dx.doi.org/10.1038/sj.bjc.6605104.
    10.1038/sj.bjc.6605104
Preprint
  1. Ana Amaral; DANIEL DELGADO BELLIDO; Esteban Zamudio-Martínez; Monica Fernandez-Cortes; Ana Belen Herrera-Campos; Joaquin Olmedo-Pelayo; Carmen Jordan-Perez; et al. "VE-Cadherin modulates ß-catenin/TCF-4 to enhance Vasculogenic Mimicry". 2022. http://dx.doi.org/10.21203/rs.3.rs-2069549/v1.
    10.21203/rs.3.rs-2069549/v1
Activities

Oral presentation

Presentation title Event name
Host (Event location)
2023/11/14 Unraveling gene fusion dependent transcription factors in Desmoplastic Small Round Cell Tumor ASEICA 40th Anniversary Congress,
ASEICA (Coruña, Spain)
2021/12/14 Desmoplastic Small Round Cell Tumor on the spotlight- Senior Author-Oral Presentation Desmoplastic Small Round Cell Tumor on the spotlight
CIBERONC (barcelona, Spain)
2021/12/13 Dissecting the role of Rloops in Ewing sarcoma chemosensitivity- Contributing Author- Face to Face poster IV Young Researchers Meeting CIBERONC-BBN
CIBERONC (barcelona, Spain)
2021 Circulating Biomarkers in Sarcomas with Translocations https://www.youtube.com/watch?v=ARO08iHZGBc&t=940s Precision diagnostics and follow-up of sarcoma patients
Asociación Sarcomas de Galicia (Galician Sarcoma Association) ASARGA (Spain)
2018/09/06 ¿Por qué elegimos el melanoma uveal como proyecto de investigación para CIBERONC? https://www.gethi.org/contenidos/apartados/detalleApartado.aspx?idTipoApartado=i2%2F7o8SaukHJdF9r3vmW1Q%3D%3D&idCategoria=vcmxUUdhbPZVNx3%2FeyzeOQ%3D%3D&idApartado=d5XrZo1yr%2BR63bnHoZKy5A%3D%3D I Jornada GETHI CIBERONC
GETHI (Sevilla, Spain)
2017 Rationale for the combination of Lurbinectedin/Trabectedin with Olaparib (Update) Incorporating EURO-EWING 99 and EWING 2008
EURO EWING Consortium – International Clinical Trials to Improve Survival from Ewing Sarcoma (london, United Kingdom)
2016/09/09 Dual targeting of Ewing sarcoma and the tumor microenvironment PROVABES/EORTC/DKTK/EEC_WP3&4 Meeting
Transcan-2 translational cancer research program (Essen, Germany)
2016 The potential application of exosomes in the clinical setting of Ewing Sarcoma
SEAP-IP (Spanish Society of Pathology) (Madrid, Spain)
2014 Transcriptional downregulation of EWSR1-FLI1, induction of DNA damage and anti-IGF1R therapies in the treatment of Ewing Sarcoma http://www.ibis-sevilla.es/media/8087/Memoria_Anual_IBiS_2014.pdf XI Foro de Investigadores. Institute of Biomedicine of Seville
Insituto de Biomedicina de Sevilla (Sevilla, Spain)
2010 Preclinical Evaluation of OSI-906 and Trabectedin effects on Ewing Sarcoma cells 1st Annual Eurosarc Meeting
EUROSARC (Treviso)

Supervision

Thesis Title
Role
Degree Subject (Type)
Institution / Organization
2023/08 - Current Deciphering the role of membrane Nucleolin in newly engineered in vitro models of Prostate Cancer
Co-supervisor
Mestrado em Biotecnologia Farmacêutica (Master)
Tumor Microenvironment and Targeted Therapies group-CNC-UC, Portugal
2021 - 2023 Desmoplastic Small Round Cell Tumor on the spotlight: Comprehensive molecular and functional characterization of new biomarkers and actionable targets
Co-supervisor
Instituto de Biomedicina de Sevilla, Spain
2021/09 - 2022/06 Genomic and functional studies in clear cell sarcoma models
Co-supervisor
Biomedicina (Degree)
Universidad de Sevilla, Spain
2020 - 2021 Uveal Melanoma: New Therapeutic Opportunities
Co-supervisor
Medicina y Cirugia (Degree)
Universidad de Sevilla-Facultad de Medicina, Spain
2017 - 2021 Endoglin in Ewing Sarcoma: from the biological relevance to a clinical strategy
Co-supervisor
Instituto de Biomedicina de Sevilla, Spain
2019 - 2020 New contributions on the Desmoplastic Small Round Cell Tumor: establishment of pre-clinical models for the identification of new targets and biomarkers
Co-supervisor
Master en Biomedicina (Master)
Instituto de Biomedicina de Sevilla, Spain
2018 - 2019 Endoglin/ALCAM as potential therapeutic targets in Clear Cell Sarcoma and Desmoplastic Small Round Cell Tumor
Co-supervisor
Universidad de Sevilla-Biomedicina (Degree)
2017 - 2018 Generation of knockout models for ALCAM of Uveal Melanoma and Ewing sarcoma
Co-supervisor
Biomedicina (Degree)
Universidad de LLeida Biomedicina , Spain

Event organisation

Event name
Type of event (Role)
Institution / Organization
2024/03/08 - 2024/03/08 Outreach activity at the Almas de Freire Primary School. Workshop: " O que são células?" "Como funcionam as vacinas?" "O que é a luz?" (2024/03/08 - 2024/03/08)
Workshop (Co-organisor)
Universidade de Coimbra, Portugal
2023/02/11 - 2023/02/11 Outreach Activity at the Almas de Freire Priimary School: Workshop: "O que fazem os investigadores?" (2023/02/11 - 2023/02/11)
Workshop (Co-organisor)
Escola Almas de Freire, Santa-Clara, Portugal

Universidade de Coimbra, Portugal

Event participation

Activity description
Type of event
Event name
Institution / Organization
2022/02/11 - Current CaixaResearch: Colaboración Dia Mundial del Cáncer infantil
Workshop
Dia Mundial del Cáncer infantil
Obra Social La Caixa, Spain
2020/02/11 - Current Women In Science, February 11. “Meet Our Researchers” Science Dissemination Activities with children and high school students https://twitter.com/LabHuvr/status/1368943413706584073/photo/1
Seminar
Women In Science, February 11. “Meet Our Researchers”
2019 - Current Science Dissemination Activities with children and high school students Science Fair-Seville https://twitter.com/LabHuvr/status/1129309616288993280/photo/1
Workshop
Science Fair-Seville
2015/02/09 - Current TUMOR MICROENVIRONMENT IN EWING SARCOMA. SEARCH FOR NEW DIAGNOSTIC TOOLS, AND THERAPEUTIC APPROACHES
Seminar
Seminario Program de Onco-Hematología y Genética
Hospital Universitario Virgen del Rocío, Spain
2024/03/05 - 2024/03/05 Outreach activity at the UC Exploratório - Ciência Viva Coimbra for pre-schoolers " O que é o DNA?"
Workshop
" O que é o DNA?"
UC Exploratório - Ciência Viva Coimbra , Portugal
2022/06/20 - 2022/06/23 Exploring the role of Endoglin in the aggressiveness of Ewing and Clear Cell Sarcoma Poster Presentation First author
Congress
EACR 2022 Congress - Innovative Cancer Science
European Association For Cancer Research, United Kingdom
2022/06/20 - 2022/06/23 Optical Genome Mapping: Unravelling the genomic landscape of Solitary Fibrous Tumor Poster Presentation Collaborator author
Congress
EACR 2022 Congress - Innovative Cancer Science: Translating Biology to Medicine
European Association For Cancer Research, United Kingdom
2022/06/20 - 2022/06/23 Desmoplastic Small Round Cell Tumor: modelling the disease Poster Presentation Senior author
Congress
EACR 2022 Congress - Innovative Cancer Science: Translating Biology to Medicine
European Association For Cancer Research, United Kingdom
2021/12/10 - 2021/12/11 100 years Ewing Sarcoma: Learning from the past, Challenges for the future
Congress
100 years Ewing Sarcoma: Learning from the past, Challenges for the future
Sarcoma Patients EuroNet EV, Germany
2018 - 2018 Unravelling endoglin as a potential therapeutic target for the treatment of uveal melanoma First author, poster presentation https://www.sciencedirect.com/science/article/pii/S2059702920320421
Congress
EACR- 25
European Association For Cancer Research, United Kingdom

Association member

Society Organization name Role
2019 - Current Member of the GETHI network. (Spanish group of Orphan and infrequent tumors) Membro
2018 - Current CIBERONC network (Cancer Network Biomedical Research Center), Low Prevalence Tumours Program Membro Adscrito a Grupo de Trabalho
2017 - Current Spanish group for sarcoma research (Grupo GEIS) Membro
2008 - Current Ordem dos Farmacêuticos Mem
2016 - 2020 The European Association for Cancer Research EACR ambassador (From 2016-2020)
2016 - 2020 Associação Portuguesa de Investigação em Cancro ASPIC Membro

Committee member

Activity description
Role
Institution / Organization
2019 - Current Member of the Immunology central working
Member
Centro de Investigación Biomédica en Red de Cáncer, Spain

Course / Discipline taught

Academic session Degree Subject (Type) Institution / Organization
2024 - Current Mestrado Biotecnologia Farmaceutica-Módulo VI: Biofármacos na Prática Clínica Mestrado em Biotecnologia Farmacêutica (Mestrado) Universidade de Coimbra Faculdade de Farmácia, Portugal
2023 - Current Mestrado Biotecnologia Farmaceutica-Módulo VI: Biofármacos na Prática Clínica Mestrado Biotecnologia Farmaceutica-Módulo VI (Mestrado) Universidade de Coimbra Faculdade de Farmácia, Portugal

Evaluation committee

Activity description
Role
Institution / Organization Funding entity
2021 - Current Expert, external reviewer for the Spanish National Research Agency in 22 projects/grants

Interview (newspaper / magazine)

Activity description Newspaper / Forum
2019 Awarded EACR travel grant for an international short-stay. https://magazine.eacr.org/it-was-a-pleasure-ana-amaral-eacr-travel-fellow/ https://magazine.eacr.org/it-was-a-pleasure-ana-amaral-eacr-travel-fellow/

Journal scientific committee

Journal title (ISSN) Publisher
2020 - Current Frontiers in Immunology and Frontiers in Oncology Frontiers
2022/12 - 2023/05 Frontiers in Immunology (1664-3224)

Mentoring / Tutoring

Topic Student name
2020 - 2023 Desmoplastic Small Round Cell Tumor on the spotlight: Comprehensive molecular and functional characterization of new biomarkers and actionable targets Laura Lobo Selma
Distinctions

Award

2023 HORIZON-WIDERA-2022-TALENTS-04
European Commission, Belgium
2022 CIBERONC Travel Grant 2022-international fellowship
Centro de Investigación Biomédica en Red de Cáncer, Spain
2019 "Juan de la Cierva" incorporation grant for a Post-Doctoral position
España Ministerio de Ciencia e Innovación, Spain
2018 CIBERONC Travel grant for an international fellowship
Centro de Investigación Biomédica en Red de Cáncer, Spain
2018 EACR travel grant for an international short-stay
European Association For Cancer Research, United Kingdom
2010 PhD grant funded by the Fundação para a Ciência e Tecnologia, Portugal
Fundação para a Ciência e a Tecnologia, Portugal